Chargement en cours...

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma

Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther Oncolytics
Auteurs principaux: Federico, Aniello, Steinfass, Tamara, Larribère, Lionel, Novak, Daniel, Morís, Francisco, Núñez, Luz-Elena, Umansky, Viktor, Utikal, Jochen
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327877/
https://ncbi.nlm.nih.gov/pubmed/32637583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.06.001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!